DigniCap provides clinically superior scalp cooling to minimize chemo-induced hair loss in patients with solid tumors. FDA cleared since 2015, DigniCap has been used successfully by thousands of patients worldwide. In the multi-center pivotal trial DigniCap prevented hair loss in 66.3% of patients with breast cancer receiving chemotherapy (JAMA February 2017). Now available is the next generation DigniCap Delta - smaller, advanced cooling, easier for staff & patients, with CE Mark and FDA clearance. To provide DigniCap at your facility email info@dignicap.com or visit www.dignicap.com.